-
US court’s decision to deny appeal to Jacobus Pharmacy
Hey all!
As you know, in October the decision was made to attempt to repeal a “District Court decision upholding the U.S. Food and Drug Administration’s (FDA) approval of another amifampridine product, Ruzurgi®, for pediatric patients with Lambert-Eaton myasthenic syndrome (LEMS) despite existing Orphan Drug exclusivity for Catalyst’s Firdapse® (amifampridine) Tablets 10 mg.”
As of yesterday, the request to appeal was denied. The court ruled that Catalyst has market exclusivity for seven years due to the Orphan Drug Act.
If you are a patient who is still taking Ruzurgi, you will need to make the transition to Firdapse instead.
If you need help with this, Catalyst pathways is here to help you with the process and provide financial aid if needed.
If you’ve already made the switch, can you share your experiences here so others can read about them.
-
0 Replies
Sorry, there were no replies found.
Log in to reply.